Investigational New Drugs · 1991 · 39 citations · 3 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyNeoplasiaPancreatic CancerPancreatic DiseasesPharmacodynamics Of Anticancer AgentsPharmacodynamics Of Anticancer DrugsPharmacokinetics Of Anticancer DrugsPancreatic Cancer PharmacotherapyPhase Ii InvestigationStudy Phase
Twenty-three patients with advanced pancreatic adenocarcinoma were treated with Pibenzimol utilizing a daily intravenous schedule for five days. There were no objective responses seen. The major toxicity was pancreatic with grade 3 hyperglycemia in eleven patients. Pibenzimol is inactive in patients with advanced pancreatic adenocarcinoma.
3